ATE305300T1 - Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren - Google Patents
Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumorenInfo
- Publication number
- ATE305300T1 ATE305300T1 AT01952097T AT01952097T ATE305300T1 AT E305300 T1 ATE305300 T1 AT E305300T1 AT 01952097 T AT01952097 T AT 01952097T AT 01952097 T AT01952097 T AT 01952097T AT E305300 T1 ATE305300 T1 AT E305300T1
- Authority
- AT
- Austria
- Prior art keywords
- cyclopamine
- tumors
- cell carcinoma
- basal cell
- tumor
- Prior art date
Links
- QASFUMOKHFSJGL-LAFRSMQTSA-N Cyclopamine Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H](CC2=C3C)[C@@H]1[C@@H]2CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C QASFUMOKHFSJGL-LAFRSMQTSA-N 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- QASFUMOKHFSJGL-UHFFFAOYSA-N cyclopamine Natural products C1C=C2CC(O)CCC2(C)C(CC2=C3C)C1C2CCC13OC2CC(C)CNC2C1C QASFUMOKHFSJGL-UHFFFAOYSA-N 0.000 title abstract 3
- 206010004146 Basal cell carcinoma Diseases 0.000 title 1
- 241000027355 Ferocactus setispinus Species 0.000 abstract 2
- 230000006907 apoptotic process Effects 0.000 abstract 2
- 230000011664 signaling Effects 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- 230000008034 disappearance Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/TR2001/000027 WO2002078703A1 (en) | 2001-07-02 | 2001-07-02 | Use of cyclopamine in the treatment of basal cell carcinoma and other tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE305300T1 true ATE305300T1 (de) | 2005-10-15 |
Family
ID=21619326
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01952097T ATE305300T1 (de) | 2001-07-02 | 2001-07-02 | Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren |
| AT02736467T ATE299022T1 (de) | 2001-07-02 | 2002-04-19 | Verwendung von cyclopamine zur herstellung eines arzneimittels zur behandlung von psoriasis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02736467T ATE299022T1 (de) | 2001-07-02 | 2002-04-19 | Verwendung von cyclopamine zur herstellung eines arzneimittels zur behandlung von psoriasis |
Country Status (14)
| Country | Link |
|---|---|
| EP (4) | EP1561464A3 (enExample) |
| JP (3) | JP2004536045A (enExample) |
| KR (1) | KR20090125833A (enExample) |
| CN (2) | CN1525859B (enExample) |
| AT (2) | ATE305300T1 (enExample) |
| AU (1) | AU2001272892B8 (enExample) |
| BR (1) | BR0117063A (enExample) |
| CA (1) | CA2452151C (enExample) |
| DE (2) | DE60113733T2 (enExample) |
| DK (2) | DK1401438T3 (enExample) |
| ES (3) | ES2250434T3 (enExample) |
| PT (1) | PT1411938E (enExample) |
| RU (1) | RU2312661C2 (enExample) |
| WO (2) | WO2002078703A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
| US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| CA2452152A1 (en) | 2001-07-02 | 2002-10-10 | Sinan Tas | Use of cyclopamine in the treatment of psoriasis |
| US20170326118A1 (en) | 2001-07-02 | 2017-11-16 | Sinan Tas | Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells |
| EP1561464A3 (en) * | 2001-07-02 | 2007-04-25 | Sinan Tas | Use of cyclopamine in the treatment of basal cell carcinoma and other tumors |
| EP2404602A1 (en) | 2005-08-22 | 2012-01-11 | The Johns Hopkins University | Hedgehog pathway antagonists to treat cancer |
| ES2618785T3 (es) | 2005-10-31 | 2017-06-22 | Oncomed Pharmaceuticals, Inc. | Composiciones y métodos para tratar el cáncer basados en receptores FZD humanos |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| CN103435694A (zh) * | 2006-10-31 | 2013-12-11 | 美国政府卫生与公共服务部 | Smoothened多肽及使用方法 |
| TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類 |
| WO2008092002A2 (en) | 2007-01-24 | 2008-07-31 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
| EP2129677B1 (en) | 2007-03-07 | 2014-12-17 | Infinity Discovery, Inc. | Heterocyclic cyclopamine analogs and methods of use thereof |
| NZ579356A (en) | 2007-03-07 | 2012-04-27 | Infinity Pharmaceuticals Inc | Cyclopamine lactam analogs and methods of use thereof |
| JP5639895B2 (ja) | 2007-12-27 | 2014-12-10 | インフィニティ ファーマスーティカルズ、インク． | 立体選択的還元方法 |
| CN101990542A (zh) * | 2008-02-08 | 2011-03-23 | 德克萨斯大学董事会 | 环巴胺酒石酸盐及其用途 |
| CA2738485A1 (en) | 2008-09-26 | 2010-04-01 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| US20110275576A1 (en) * | 2009-01-06 | 2011-11-10 | Utah State University | Carbohydrate-Cyclopamine Conjugates as Anticancer Agents |
| JP2009143963A (ja) * | 2009-03-25 | 2009-07-02 | Sinan Tas | 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物 |
| JP6141015B2 (ja) | 2009-08-05 | 2017-06-07 | インフィニティ ファーマスーティカルズ、インク． | シクロパミン類似体の酵素によるアミノ基転移 |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| CA2794674A1 (en) | 2010-04-01 | 2011-10-06 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| US9376447B2 (en) | 2010-09-14 | 2016-06-28 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
| CA2887711A1 (en) | 2012-10-23 | 2014-05-01 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using wnt pathway-binding agents |
| CN105073195A (zh) | 2013-02-04 | 2015-11-18 | 昂科梅德制药有限公司 | 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测 |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| WO2015096654A1 (zh) * | 2013-12-26 | 2015-07-02 | 中国科学院上海生命科学研究院 | Shh信号通路特异性抑制剂的应用 |
| BR112017026103B1 (pt) | 2015-06-04 | 2023-10-03 | Sol-Gel Technologies Ltd | Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos |
| WO2017139497A1 (en) * | 2016-02-11 | 2017-08-17 | PellePharm, Inc. | Hedgehog inhibitor for use in relief of and treatment of pruritus or itching |
| CA3227688A1 (en) | 2021-09-13 | 2023-03-02 | Sinan Tas | Effective interventions with aging and diseases of aging of human and their consequences |
| CN114292279B (zh) * | 2022-01-07 | 2023-05-09 | 吉林省农业科学院 | 一种藜芦抗癌有效成分环杷明提取与分离方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851993A (en) * | 1994-06-13 | 1998-12-22 | Biotie Therapies Ltd. | Suppression of tumor cell growth by syndecan-1 ectodomain |
| JP5067986B2 (ja) * | 1998-04-09 | 2012-11-07 | ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン | ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用 |
| WO2000016772A1 (en) * | 1998-09-23 | 2000-03-30 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
| US6291516B1 (en) * | 1999-01-13 | 2001-09-18 | Curis, Inc. | Regulators of the hedgehog pathway, compositions and uses related thereto |
| GB0013674D0 (en) * | 1999-06-08 | 2000-07-26 | Lorantis Ltd | Therapeutic use |
| WO2001027135A2 (en) * | 1999-10-13 | 2001-04-19 | Johns Hopkins University School Of Medicine | Regulators of the hedgehog pathway, compositions and uses related thereto |
| CA2392958A1 (en) * | 1999-11-30 | 2001-06-07 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
| CU23175A1 (es) * | 2000-07-17 | 2006-09-22 | Ct De Investigacion Y Desarrol | Formulacion liposomica de propionato de clobetasol |
| EP1561464A3 (en) * | 2001-07-02 | 2007-04-25 | Sinan Tas | Use of cyclopamine in the treatment of basal cell carcinoma and other tumors |
| CA2452152A1 (en) * | 2001-07-02 | 2002-10-10 | Sinan Tas | Use of cyclopamine in the treatment of psoriasis |
-
2001
- 2001-07-02 EP EP05008758A patent/EP1561464A3/en not_active Withdrawn
- 2001-07-02 WO PCT/TR2001/000027 patent/WO2002078703A1/en not_active Ceased
- 2001-07-02 EP EP20140196071 patent/EP2862570A1/en not_active Withdrawn
- 2001-07-02 ES ES01952097T patent/ES2250434T3/es not_active Expired - Lifetime
- 2001-07-02 AT AT01952097T patent/ATE305300T1/de not_active IP Right Cessation
- 2001-07-02 JP JP2002576969A patent/JP2004536045A/ja active Pending
- 2001-07-02 AU AU2001272892A patent/AU2001272892B8/en not_active Ceased
- 2001-07-02 EP EP01952097A patent/EP1401438B1/en not_active Revoked
- 2001-07-02 DE DE60113733T patent/DE60113733T2/de not_active Expired - Lifetime
- 2001-07-02 CN CN018234429A patent/CN1525859B/zh not_active Expired - Fee Related
- 2001-07-02 ES ES10163813.8T patent/ES2534400T3/es not_active Expired - Lifetime
- 2001-07-02 BR BR0117063-5A patent/BR0117063A/pt active Search and Examination
- 2001-07-02 CA CA2452151A patent/CA2452151C/en not_active Expired - Fee Related
- 2001-07-02 DK DK01952097T patent/DK1401438T3/da active
- 2001-07-02 EP EP10163813.8A patent/EP2216022B1/en not_active Expired - Lifetime
-
2002
- 2002-04-19 DK DK02736467T patent/DK1411938T3/da active
- 2002-04-19 DE DE60204966T patent/DE60204966T2/de not_active Expired - Lifetime
- 2002-04-19 RU RU2004103074/15A patent/RU2312661C2/ru not_active IP Right Cessation
- 2002-04-19 CN CNB02813429XA patent/CN1230169C/zh not_active Expired - Fee Related
- 2002-04-19 PT PT02736467T patent/PT1411938E/pt unknown
- 2002-04-19 WO PCT/TR2002/000017 patent/WO2002078704A1/en not_active Ceased
- 2002-04-19 ES ES02736467T patent/ES2246011T3/es not_active Expired - Lifetime
- 2002-04-19 AT AT02736467T patent/ATE299022T1/de not_active IP Right Cessation
-
2003
- 2003-03-17 KR KR1020097022024A patent/KR20090125833A/ko not_active Ceased
-
2010
- 2010-02-10 JP JP2010028010A patent/JP5424923B2/ja not_active Expired - Fee Related
-
2013
- 2013-09-18 JP JP2013193304A patent/JP2014028834A/ja not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE305300T1 (de) | Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren | |
| DE60037394D1 (de) | VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE | |
| DE60109589D1 (de) | Pharmazeutische zusammensetzung zur behandlung von akutem schmerz, chronischem schmerz und/oder neuropathischem schmerz und migräne | |
| ATE422358T1 (de) | Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungen | |
| ATE305306T1 (de) | Reboxetin zur behandlung von peripheren neuropathien | |
| DE50310516D1 (de) | Fredericamycin-derivate | |
| DE602005026276D1 (de) | Myricitrin verbindungen zur behandlung von schlafstörungen | |
| ATE406897T1 (de) | Kombination von et-743 mit 5-fluorouracil pro- drugs zur behandlung von krebs | |
| UA72927C2 (uk) | Композиція для лікування печінково-клітинного раку, що містить доцетаксель | |
| ATE309817T1 (de) | Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs | |
| DE50114605D1 (de) | No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz | |
| EP1694364A4 (en) | BREAST CANCER TREATMENT AND PREVENTION SYSTEM | |
| ATE380554T1 (de) | Verwendung von xenon mit hypothermie zur behandlung von neugeborenen-asphyxie | |
| ATE230995T1 (de) | Medikament zur prophylaxe und/oder behandlung des mammarkarzinoms enthaltend einen steroidalen aromataseinhibitor | |
| DE60128009D1 (de) | Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma | |
| DE60141979D1 (de) | Verwendung von endothelin antagonisten zur behandlung von knochenkrebs und damit verbundenen schmerzen | |
| BRPI0410998A (pt) | derivados de indol com efeito de indução de apoptose | |
| ATE512664T1 (de) | Sphingomyelin enthaltende zusammensetzung zur behandlung der rheumatoiden arthritis | |
| DE60107900D1 (de) | Pharmazeutische Zusammensetzung und Nahrungsmittel zur Behandlung von Gehirnödem | |
| ATE302009T1 (de) | Ubichinon qn zur behandlung von migräneschmerzen | |
| ATE353664T1 (de) | Hcg therapie zur behandlung von metastatischem brustkrebs | |
| ATE484280T1 (de) | Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma | |
| ATE386748T1 (de) | Verwendung von liganden von cd52 antigen zur behandlung von soliden tumoren und von knochenkrebserkrankungen | |
| SE0101258D0 (sv) | Treatment of low back pain and whiplash associated disorder | |
| ATE337783T1 (de) | Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1401438 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |